

SYSTEMATIC REVIEW OPEN



Rethinking Alzheimer's: novel miRNAs illuminate a disease beyond the brain

JS Novotný^{1,2,5}, M Čarná^{1,5}, EB Dammer³, Z Mao³ and GB Stokin^{1,4}✉

© The Author(s) 2026

Alzheimer's disease (AD) poses major health, social and economic challenges to the modern world. Despite the advances in understanding AD, our knowledge about its pathogenesis remains incomplete. Recent data suggest that circulating microRNAs (miRNAs) undergo complex changes in AD. Since these changes are yet to be comprehensively characterized, we investigated miRNAs in the context of AD using two meta-analytical approaches. We reproducibly identified 2895 miRNAs in a cohort of 4186 individuals from 22 studies. Here we show that 194 miRNAs exhibited widespread changes in AD, including some novel miRNAs not yet linked to AD. These novel AD miRNAs broaden the landscape of research on the role of miRNAs in AD. Targets of these miRNAs further uncovered many biological pathways that, to date, remain poorly understood in AD with several "AD miRNAs" never described in the brain. "AD miRNAs" described outside the brain significantly influenced interleukin signaling, Toll receptor signaling, p38 MAPK pathway and insulin/IGF pathway. Our results reveal a greater complexity of biological pathways involved in AD than previously thought and raise the question of whether AD is indeed a brain-specific and not a systemic disorder. These findings advance current understanding of AD pathogenesis and lay the ground for the development of next-generation AD biomarkers and design of miRNA-engaged therapies.

Molecular Psychiatry; <https://doi.org/10.1038/s41380-026-03487-6>

INTRODUCTION

Short non-coding RNAs with antisense complementarity, known as microRNAs (miRNAs), were originally discovered to post-transcriptionally regulate gene expression during roundworm development [1, 2]. Some miRNAs contain sequence codes (EXOMOTIFS) that are instructive of their secretion [3, 4] either packaged into vesicles or bound to proteins [5, 6]. Secreted miRNAs were identified in all major body fluids [7]. By circulating, they allow for long-distance gene regulation and coordinated crosstalk between tissues [8].

Abnormalities in miRNAs have been described in many human disorders from cancer [9] to Alzheimer's disease (AD) [10]. AD is the most common neurodegenerative disorder characterized by abnormal levels or processing of the amyloid precursor protein (APP) leading to amyloid plaques and aberrant phosphorylation of the microtubule-associated protein tau [11]. Dysregulated microtubule-dependent transport, mediated by molecular motors, underlies axonal transport impairments and pathology in AD [12]. Several other molecules and processes have been linked to AD pathogenesis including ApoE ϵ 4 genotype [13], the insulin pathway [13] and past infections [14]. Accumulating evidence also suggests a degree of mutual exclusivity between development of cancer and AD [15, 16]. Changes in miRNAs have been reported in the brain [17], cerebrospinal fluid [18] and plasma [19, 20] in AD. Recent work showed that abnormalities in miRNAs

take place already during physiological aging and that miRNA changes in AD represent at least in part a pathological exacerbation of physiological aging [21]. We here examined systematically circulating miRNAs in AD using two meta-analytical approaches and rigorous data selection. We found that miRNAs changed in AD, including a number of novel miRNAs not yet linked to AD, target many biological pathways that are largely unaccounted for in the context of AD with several of them never described in the brain. These findings reveal greater complexity of biological processes involved in AD than previously thought and raise the question of whether AD is not a systemic rather than a brain disorder.

METHODS

Study design

The study followed PRISMA 2020 reporting guidelines [22]. Study resources for meta-analysis were obtained by searching PubMed, PubMed Central (PMC) and Gene Expression Omnibus (GEO) repository using keywords [miRNA AND (AD OR alzheimer) AND (plasma OR serum OR blood)]. All studies reported to investigate human circulating miRNAs in AD until October 1, 2024, that provided either complete raw miRNA expression data or miRNA differential expression (DE) data with fold-changes and P-values for all analyzed miRNAs (significant and non-significant miRNA

¹Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. ²Department of Psychology and Abnormal Psychology, Faculty of Education, Palacký University Olomouc, Olomouc, Czech Republic. ³Departments of Pharmacology and Chemical Biology and Neurology, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, USA. ⁴Department of Neurology, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK. ⁵These authors contributed equally: JS Novotný, M Čarná. ✉email: gbstokin@alumni.ucsd.edu

Received: 4 August 2025 Revised: 6 January 2026 Accepted: 31 January 2026

Published online: 13 February 2026

Table 1. Main characteristics of studies included to meta-analysis.

Study	Sample size (AD + CN)	miRNAs analyzed	Source	Expression analysis	Data
Batabyal 2023	18 + 14	2578	Serum	microArray	DE results
Čarná 2023	9 + 11	2578	Plasma	microArray	DE results
Denk 2018	47 + 38	87	Serum	RT-qPCR	Raw expression
Dong 2015	127 + 123 (48 + 48 used)	16	Serum	RT-qPCR	DE results
Dong 2021	8 + 8	1957	Blood	RNAseq	Raw expression
Fitz 2021	23 + 16	357	Plasma	RNAseq	DE results
Keller 2016 set 1	54 + 22	551	Blood	RNAseq	DE results
Keller 2016 set 2	49 + 55	494	Blood	RNAseq	DE results
Kumar 2017	10 + 14	68	Serum	RT-qPCR	DE results
Leidinger 2013	106 + 22 (48 AD used)	366	Blood	RNAseq	Raw expression
Lu 2021	1021 + 288	2562	Serum	microArray	DE results
Ludwig 2019	145 + 214	21	Blood	RT-qPCR	Raw expression
Lugli 2015	35 + 35	463	Plasma	RNAseq	Raw expression
Palade 2024	33 + 71	299	Plasma	RNAseq	DE results
Nie 2020	5 + 20	100	Plasma	RNAseq	Raw expression
Shigemizu 2019	1021 + 288	2562	Serum	microArray	Raw expression
Visconte 2023	11 + 20	255	Plasma	microArray	DE results
Wang 2022	47 + 62	1957	Plasma	RNAseq	DE results
Wen 2024	28 + 21	786	Serum	RNAseq	Raw expression
Wu 2020 set 1	40 + 31	72	Plasma	RNAseq	DE results
Wu 2020 set 2	48 + 22	191	Plasma	RNAseq	DE results
Zhai 2024	6 + 6	2263	Plasma	microArray	DE results

changes) were included in the meta-analysis. Research involving non-human subjects, studies not reporting original research, research of miRNAs isolated from sources other than plasma, serum or blood, reports without full text, experiments presented by incomplete results, for example experiments reporting only miRNAs with significant raw or differential expression data, but no information about miRNAs with non-significant changes, and contributions presenting insufficient and/or missing data were excluded.

Data extraction

Three researchers conducted literature search, retrieved full texts, assessed study resources, and extracted data according to inclusion and exclusion criteria. The extracted data included first author, year of publication, sample size, source of miRNAs (plasma, serum, blood), number of analyzed miRNAs, type of data (raw expression or DE with fold-changes and P-values), type of DE analysis, and raw expression data/DE analysis results for all analyzed miRNAs. A total of 41 (0.2%) rows with missing and erroneous values in the input data were removed prior to meta-analysis. No missing values imputation was performed. To limit the bias from random one-off effect, only miRNAs identified by at least three independently reported studies were included in the analyses.

Quality assessment

As recommended by the Cochrane Collaboration [23], all studies selected for this analysis underwent quality assessment. The quality was assessed using the Newcastle-Ottawa Scale, which evaluates selection of study groups, comparability of groups and assessment of outcomes [24]. In addition, vote-counts of the general trend in directionality of miRNA changes in AD patients compared with healthy subjects were calculated by establishing the level of concordance in directionality of individual miRNA expression changes (up- or down-regulation) reported in different studies.

Statistical analysis

All statistical analyses were performed in RStudio (v.2024.04.2 build 764, with R environment v.4.4.0). All P-values < 0.05 or $-\log_{10}$ P-values > 1.301 were considered significant. DE results for studies with raw expression data were calculated using *deseq2* and *limma* packages or using the Wilcoxon test with the Benjamini-Hochberg correction. If statistical method was described in the original study, we used the same procedure in our analysis. Differences between groups of count values were analyzed using Pearson's chi-square test. The conditions for the applicability of the statistical tests (such as normality of distribution, etc.) were verified prior to the analysis.


Fold-change-based meta-analysis

In the meta-analysis, the effects of individual plasma miRNAs in AD patients compared with healthy subjects was examined using the *Amanida* package for R [25]. This method provided for each miRNA information about the directionality of miRNA expression change (up- or down-regulated), compound \log_2 fold-change and compound P-value. Compound \log_2 fold-change was calculated as the average of the individual log-transformed (base 2) fold-changes from the input studies weighted by study sizes. The compound P-value was calculated using a Fisher-based weighted P-value combination of the individual P-values from the input studies weighted by the study size.

In addition, pseudo-T-scores were calculated using the formula $[(\text{avg}(\log FC) / \text{sd}(\log FC) * \sqrt{n_{\text{studies}}})]$ [26]. This score measures consistency in directionality in miRNA expression changes, with absolute values above 1.96 indicating the highest consistency in up- or down-regulated miRNAs across the studies. The compound P-values and the pseudo-T-scores were used in combination to identify the most significant and consistent miRNA changes in AD patients compared with healthy controls across the studies.

Weighted miRNAs co-expression network meta-analysis

Clusters of similarly behaving miRNA profiles in AD patients were identified using a weighted miRNA co-expression network analysis



(WmiRNACNA). This analysis was based on the general workflow derived from the weighted gene co-expression network analysis (WGCNA) but with the input represented by the \log_2 fold-change values from individual studies describing differences in miRNAs expression in AD patients compared with healthy subjects. A

weighted adjacency matrix was computed by calculating the signed biweight midcorrelation $[cor_{ij} = (1 + bicor) / 2]$ between all miRNAs. Due to different number of studies for each miRNA, 'pairwise.complete.obs' command was used. Optimal soft-threshold 18 was next calculated using the WGCNA::pickSoftThreshold.fromSimilarity

Fig. 1 Amanida-based meta-analysis. **A** Volcano plot showing Amanida-derived meta-analysis results. Red circles correspond to miRNAs with compound P-values $-\log_{10} > 1.301$ and pseudo-T-scores > 1.96 , yellow and grey circles correspond to miRNAs with compound P-values $-\log_{10} > 1.301$, respectively. **B** Venn networks showing the prevalence of significantly up- (pink) and down- (green) regulated miRNAs described (yellow) or not (grey) in the brain in AD patients compared with healthy subjects (average expression level ≥ 10 rpmm). **C** Presence of “AD miRNAs” in individual tissues based on the miRATissueAtlas version 2025 (one miRNA was not present in the TissueAtlas database). Only 10 tissues with the highest average miRNA expressions (rpmm normalized counts) are displayed for each miRNA changed in AD. **D** The top 10 most significantly enriched and top neurodegeneration-related PANTHER knowledgebase forecast biological pathways based on the strong targets of significantly up- and down-regulated miRNAs found in brain or other tissues in AD patients compared with healthy subjects. **E** Sankey plot showing targets known to be involved in the pathogenesis of AD including targets involved in impaired axonal transport for up- (pink) and down- (green) regulated miRNAs in AD patients compared with healthy subjects. MiRNAs with more than 3 related AD targets are displayed in the left panel. **F** Combined barplot of Vesiclepedia-predicted proportions of miRNAs found in extracellular vesicles (EVs) ($P = 0.708$) and percentage of secretion-promoting EXO motifs ($P = 0.00002$) in AD patients compared with healthy subjects.

function (with a resulting $R^2 = 0.868$) and the correlation matrix raised to this power. The signed Topological Overlap Matrix (TOM) was obtained using the WGCNA::TOMsimilarity function and acceptable scale-free network properties of the matrix verified. This matrix was converted to a dissimilarity matrix using 1-TOM. Last, a hierarchical cluster analysis using Ward's D^2 method was performed. The obtained dendrogram was partitioned into individual clusters using the function WGCNA::cutreeDynamic (method = 'hybrid', deepSplit=2, pamStage=T, pamRespectsDendro=T, minClusterSize=10). Subsequently, similar clusters were merged using the WGCNA::mergeCloseModules function (with Module Eigengene dissimilarity threshold of 0.4).

In traditional WGCNA, clusters of interest are identified by correlating kME values (eigengenes of modules) with defined phenotypic information about compared samples, for example, AD patients versus healthy subjects. Since our data do not allow direct comparison between AD patients and healthy subjects in terms of similarly behaving miRNAs, AD-related clusters were identified using the following criteria: (1) cluster miRNAs' \log_2 fold-change values were significantly different from zero based on one-sample Mann-Whitney-Wilcoxon test, (2) cluster miRNAs' \log_2 FC Q1-Q3 range was outside of zero and, (3) at least 50% of miRNAs in a cluster were significantly different in AD compared with healthy subjects according to the Amanida-based meta-analysis.

MiRNA targets prediction

Prediction of the miRNA targets was performed by miRTargetLink 2.0 (<https://ccb-compute.cs.uni-saarland.de/mirtargetlink2/>), which works with validated (miRTarBase 8.0) and predicted (mirDIP, miRDB) miRNA targets from Homo sapiens [27]. The final set of target genes corresponding to significantly changed miRNAs in AD compared with healthy subjects was established only after removal of duplicate results. MiRNAs were classified as “AD-known” if they had at least one experimentally validated target (miRTarBase 8.0) recognized to be directly implicated in AD pathogenesis (e.g., APP, ADAM10, BACE1, PSEN1/2, MAPT). MiRNAs without validated interactions with AD-related genes were labeled “AD-unknown”. This division into “AD-known” and “AD-unknown” miRNAs was used only for data interpretation purposes and did not affect any statistical analyses.

Functional enrichment analysis

Functional enrichment analysis of sets of genes targeted by selected miRNAs was performed using the ShinyGO V0.80 [28]. Benjamini-Hochberg FDR correction was used to assess the significance level; 20 genes were selected as the minimum threshold for pathway size. MiRNA target functions were obtained using either REACTOME, Panther or KEGG database.

Tissue specificity and involvement in AD

TissueAtlas version 2025 was used to analyze miRNA tissue specificity [29]. The presence of miRNAs in individual tissues was verified against a matrix of average miRNA expressions from TA. Only miRNAs with average tissue expression of ≥ 10 rpmm were

included in the analyses. MiRNAs with zero expression were excluded prior to analysis.

MiRNA coding motifs

To test what proportion of miRNAs originates from EVs, we calculated percentages of plasma miRNAs corresponding to miRNAs previously identified in EVs as annotated in Vesiclepedia, a manually curated database of molecules identified in different classes of EVs [30]. To find out proportions of miRNAs harbouring EXO motifs [3], we first established which EXO/CELL motifs are present in each miRNA by cross-referencing the sequences of individual motifs against the miRNA sequences. Only complete EXO/CELL sequence in the miRNA was considered as the presence of a motif. We then calculated the sum of EXO and CELL motifs per miRNA. MiRNAs were considered carrying EXO motifs only if their miRNA sequence contained exclusively EXO motifs or the number of EXO motifs in the sequence was greater than the number of cellular retention CELL motifs.


RESULTS

Sample quality and characteristics

A search using predefined key words identified 762 publications in PubMed/PMC and 73 GEO repository datasets (Extended Data fig. 1). Abstract review excluded 555 records, because studies reported animal research, lacked original research or presented meta-analyses. Full text review excluded further 258 records reporting miRNAs analyses from sources other than plasma, serum or blood, without full-text or showing incomplete results or incomplete data. Following review of individual miRNAs reported in the remaining 22 records, an additional 245 miRNAs were excluded due to questionable reproducibility as they were not detected by more than two independent studies. The study sample passed quality control based on the Newcastle-Ottawa scale (Extended Data fig. 2). Since 82% of miRNAs showed the same direction of expression change in at least 75% of studies, no miRNAs were excluded based on vote counts (Extended Data fig. 3, Extended Data Table 3). The final study sample consisted of 2650 miRNAs in a cohort of 4186 individuals (Table 1) [21, 31–49].

Meta-analysis of circulating miRNAs in AD

To obtain a comprehensive understanding of circulating miRNAs in AD, we measured their expression in AD patients and healthy subjects. A total of 910 out of 2650 miRNAs demonstrated significant expression changes in AD (compound P-scores, Fig. 1A, Supplementary Table 1A). Only 194 of these miRNAs, however, showed the same direction of expression change (pseudo-T-scores, i.e. always up- or down-regulated) in at least 3 independent studies. 161 of these miRNAs were up- and 33 down-regulated in AD (Extended Data fig. 4, Extended Data Table 4). Targets of these “AD miRNAs” were projected to dysregulate cytokine and receptor tyrosine kinase (TRK) signaling, to repress cell death and estrogen-receptor (ER) pathways and to



accentuate signal transduction and transcription (Extended Data fig. 5, Extended Data Table 5).

We next investigated possible tissues of origin of these “AD miRNAs”. 30 and 84% of up- and down-regulated “AD miRNAs”, respectively, were previously described in the brain but

concomitantly found most also in other organs (Fig. 1B and C, Supplementary Table 1B and 1C). Key targets of brain “AD miRNAs” were predicted to dysregulate p53, insulin/IGF, Ras and interferon- γ signaling, hypoxia-response via HIF activation, and apoptosis as well as AD and Huntington’s disease (HD) pathways,

Fig. 2 Weighted miRNAs co-expression network analysis. **A** Dendrogram depicting results of hierarchical clustering, bottom color strip indicates distribution of the final 12 modules. **B** Boxplots portraying distribution of average \log_2FC values (calculated as mean of \log_2FC values from individual studies included in meta-analysis) of miRNAs in individual modules. Bottom table shows number of miRNAs in each module. Modules E, F, and K (depicted in bold) were characterized by the most significantly changed \log_2FC values ($Q1-Q3 \neq 0$) and contained the highest proportion of miRNAs significantly altered in AD as revealed by the meta-analysis. **C** Barplot showing proportion of miRNAs changed in AD patients based on meta-analysis in individual modules. E, F and K modules with most significantly increased proportions of changed miRNAs in AD patients are emphasized in bold. Modules C, G, H and L exhibit least miRNA changes. **D** Heatmaps showing presence of miRNAs from modules E, F and K in individual tissues (85 [100%], 162 [95%] and 75 [93%] of miRNAs were represented in the database). Only 10 tissues with the highest average miRNA expressions (rpmm normalized counts) are displayed for each miRNA changed in AD. **E** The top 10 most significantly enriched and neurodegeneration-related PANTHER knowledgebase forecast biological pathways based on targets of miRNAs found inside or outside the brain in modules E, F, and K. **F** Sankey diagram showing targets known to be involved in the pathogenesis of AD. MiRNAs with more than 3 related AD targets are displayed in the left panel. **G** Combined barplot of Vesiclepedia-based predicted proportions of miRNAs found in extracellular vesicles (EVs) and harboring secretion-promoting EXO motifs in WmiRNACNA clusters. Red frames indicate AD-related modules.

to accentuate CCKR, FAS and p38 MAPK signaling and Parkinson's disease (PD) pathways, and to reduce VEGF and PI3 kinase signaling (Fig. 1D, Supplementary Table 1D). Key targets of "AD miRNA" found likely to originate from outside the brain were predicted to equally dysregulate insulin/IGF, Ras and interferon- γ signaling, apoptosis and AD, HD and PD pathways and to reduce VEGF, CCKR, angiotensin II, interleukin, endothelin signaling and T cell activation. Apart from Apolipoprotein E, many molecules linked to the pathogenesis of AD including APP and tau, as well as components of axonal transport, were all found among "AD miRNA" targets (Fig. 1E, Supplementary Table 1E). Independently from their tissues of origin, miRNAs were projected to be enriched in EXO motifs in AD (Fig. 1F, Supplementary Table 1F).

WmiRNACNA in AD

To identify networks of miRNAs that are changed in AD, we developed WmiRNACNA by modifying WGCNA (in Methods). Based on \log_2 fold-changes, hierarchical clustering of 2650 miRNAs gave rise to 12 miRNA membership modules (Fig. 2A, Supplementary Table 2A). Modules E, F and K showed average \log_2 fold-change values furthest from zero (Fig. 2B, Supplementary Table 2B), and contained the highest percentages of "AD miRNAs" previously found by meta-analysis (Fig. 2C, Supplementary Table 2C). All miRNAs in these modules were upregulated. Key targets of "AD module miRNAs" were predicted to impact the same activities as targets of "AD miRNAs" identified by meta-analysis including cytokine (E and F), RTK and estrogen signaling (F) in addition to cell cycle regulation (E and K, Extended Data fig. 6, Extended Data Table 6).

We next asked whether miRNAs in "AD modules" are found predominantly in the brain. Only 21, 21 and 25% of E, F, and K module miRNAs were previously described in the brain (Fig. 2D, Supplementary Table 2D, Extended Data Table 2). The most frequent targets of these "AD module miRNAs" were projected to suppress p53, insulin/IGF, Ras, interferon- γ and PI3 kinase signaling, hypoxia-response via HIF activation, oxidative stress, B cell activation as well as AD pathways (Fig. 2E, Supplementary Table 2E). "AD module miRNAs" found outside the brain were projected to reduce interleukin signaling and Rho GTPase cytoskeletal regulation. Apart from Apolipoprotein E, all molecules linked to the pathogenesis of AD including APP and tau as well as components of the axonal transport, were found among "AD miRNA module" targets (Fig. 2F, Supplementary Table 2F). Projected frequency of miRNAs in EVs as well as enriched in EXO motifs varied significantly between modules (Fig. 2G, Supplementary Table 2G).

Key circulating miRNAs in AD

A total of 37 miRNAs were found significantly changed in AD based on both meta-analysis and the WmiRNACNA (Extended Data fig. 7, Table 2, Extended Data Table 7). Only 7 of these miRNAs were previously linked to AD with targets including APP,

ADAM10, BACE, and presenilin (Fig. 3A, Supplementary Table 3A). Targets of these "AD miRNAs" were predicted to suppress axon guidance, p53 pathway, Wnt and cadherin signaling, angiogenesis and Alzheimer's disease-presenilin pathways (Fig. 3B, Supplementary Table 3B). The other 30 miRNAs remain poorly described in the context of AD. Their targets are projected to center frequently around the CCKR signaling map and to most commonly dysregulate insulin/IGF, p38 MAPK, Toll-receptor, PDGF and the interleukin signaling pathways. The "AD miRNAs" previously linked to AD showed the highest levels of expression in liver and immune system related tissues, while poorly known miRNAs in AD were found primarily in blood and the vestibulo-cochlear complex with several orders of magnitude lower expression levels (difference 10^4 rpmm, Fig. 3C, Supplementary Table 3C). We last attempted to understand functional repercussions of changes in these key circulating "AD miRNAs". Based on Kyoto Encyclopedia of Genes and Genomes, all "AD miRNAs" were predicted to play a dominant role in axon guidance and cancer pathways (Fig. 3D, Supplementary Table 3D). In addition, "AD miRNAs" previously linked to AD were predicted to contribute to oxytocin signaling, adherent junctions, TGF β signaling, longevity, hedgehog signaling, neurotransmitter signaling and AD and neurodegeneration, while poorly described "AD miRNAs" in AD were predicted to play roles in ErbB, hippo and p53 signaling.

DISCUSSION

A major strength of this study is the rigor with which data have been collected and analyzed. Given that many studies reporting miRNA abnormalities in AD provide only data for significantly DE miRNAs, there is a risk that the observed abnormalities in individual miRNAs are biased by overestimating their significance given the lack of data on instances where the miRNAs in question did not show significant differences. To circumvent this potential bias, this meta-analysis has investigated the pooled effect of miRNA abnormalities in AD based only on studies that provided a complete set of results either from DE analyses which include also non-significantly DE miRNAs, or from a complete list of raw miRNA expression data. This study used different meta-analytic approaches, analyzing first the individual roles of the most significant miRNAs in AD and then identifying modules of miRNAs exhibiting similar behavior in AD. This multivariate approach highlights key "AD miRNAs" and contributes to understanding AD better. One potential limitation of the study is the inconsistency of naming miRNAs in the original studies. Given the evolution of miRNA nomenclature over time, for example the use of * and 3p/5p refinements, the names of miRNAs in different studies may differ, although sequence-wise they refer to the same miRNA. This issue, however, cannot be resolved within the secondary analysis without full access to sequence data and should therefore be kept in mind when interpreting our results. In the future, it would be




Fig. 3 Key AD-related miRNAs. **A** Number of miRNAs identified as known or unknown to play roles in AD pathogenesis based on their targets. Circular dendrograms show proportion of targets involved in biological processes of miRNAs known or unknown to play roles in AD pathogenesis. Minimum shared target was set to 3. **B** Most significant PANTHER knowledgebase forecast biological pathways identified for the minimum of 3 shared targets of AD known and unknown miRNAs. **C** Sankey plot showing tissue specificity for AD known and unknown miRNAs. The top 3 individual tissues per miRNA based on miRNAAtlas version 2025 database are shown (average expression level ≥ 10 rpmm). Line thickness represents the miRNA expression level in individual tissue ($\log_{10}(\text{rpmm})=1\text{to}6$). **D** Top 10 complex interactions and disease related pathways (KEGG) for AD known and AD unknown miRNAs.

Table 2. The most relevant AD-related miRNAs derived from both meta-analyses.

miR-103a-3p	miR-3927-5p	miR-4731-3p	miR-6751-3p	miR-6867-3p
miR-122-5p	miR-3973	miR-4804-3p	miR-6773-3p	miR-6890-3p
miR-2113	miR-4433b-5p	miR-5096	miR-6777-3p	miR-7109-3p
miR-3156-3p	miR-4436b-5p	miR-5584-3p	miR-6808-5p	miR-7152-5p
miR-3646	miR-4652-3p	miR-5588-3p	miR-6821-3p	miR-8485
miR-3649	miR-4700-3p	miR-659-3p	miR-6830-5p	
miR-3685	miR-4711-3p	miR-6742-3p	miR-6846-3p	
miR-371b-3p	miR-4713-5p	miR-6743-5p	miR-6866-3p	

useful to implement tools for retrospective application of currently valid miRNA nomenclature standards to earlier studies.

Using two meta-analyses, we identified a number of “AD miRNAs”. Surprisingly, many of these miRNAs have not yet been characterized as AD-related, so their identification broadens our horizons and opportunities in exploring the mechanisms of AD and the role of these miRNAs. Several molecules previously linked to the pathogenesis of AD have been identified among targets of these “AD miRNAs”. Observation that miRNAs target the entire A β pathway implicates circulating miRNAs directly in the pathogenesis of AD. Molecules involved in impaired axonal transport in AD including molecular motors, besides microtubule interacting proteins such as tau, have also been found among targets of “AD miRNAs,” further supporting a role of miRNAs in AD. Altogether, these results provide a comprehensive understanding of the contribution of circulating miRNAs in the pathogenesis of AD and, in addition, corroborate previously noted associations between miRNAs and AD molecules [50]. Studies of mechanisms underlying miRNA changes offer some evidence of dysregulated Drosha [51] and Dicer [52]. Alternatively, given that most “AD miRNAs” are enriched in EXO motifs and therefore preferentially secreted, it might well be that miRNA defects occur at the level of the endosomal/lysosomal pathway [53, 54]. Significant further work is needed to establish the mechanisms and pinpoint origins underlying systemic circulating miRNA changes in AD.

Targets of “AD miRNAs” reveal involvement of most diverse pathways in the pathogenesis of AD. Some of the targets are involved in the cell cycle and death [55] as well as in cytokine [56], estrogen [57] and insulin [58–60] signaling, which have all been previously described in AD. Other targets, for example CCKR [61–63], integrin [64], interferon- γ [65] and p53 [66, 67] signaling as well as angiogenesis [68] have hardly been accounted for in the context of AD. These pathways represent knowledge gaps in our understanding of AD. For example, miRNAs projected to dysregulate p53 in AD might provide valuable clues in understanding the interactions between cellular senescence, AD and cancer. Surprisingly, only a fraction of “AD miRNAs” has been described in the brain and at the same time, most frequently as relevant in several other tissues. This suggests that “AD miRNAs” belonging to different tissues of origin are functionally diverse in AD. This is unexpected, considering AD is thought to be a neurodegenerative disorder with etiology exclusive to the brain. There are at least two plausible explanations of this finding. First, AD pathology triggers initial miRNA changes in the brain and only later in other tissues. And second, “AD miRNAs” from other tissues are generated independently from the brain and contribute to AD pathology. Both scenarios provide support to the view that AD is a systemic disorder. In conclusion, the findings presented in this study reveal novel circulating miRNAs altered in AD that functionally not only recapitulate most well-established pathways but also uncover several unaccounted-for pathways in AD and are thus most informative about its pathogenesis. These findings offer an unprecedented opportunity to develop a next generation of biomarkers, and open novel avenues for design of AD therapies.

DATA AVAILABILITY

The data used in this study are available within the article and its supplementary materials.

REFERENCES

- Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*. 1993;75:843–54. [https://doi.org/10.1016/0092-8674\(93\)90529-y](https://doi.org/10.1016/0092-8674(93)90529-y)
- Ambros V. microRNAs: tiny regulators with great potential. *Cell*. 2001;107:823–6. [https://doi.org/10.1016/S0092-8674\(01\)00616-x](https://doi.org/10.1016/S0092-8674(01)00616-x)
- Garcia-Martin R, Wang G, Brandão BB, Zanotto TM, Shah S, Kumar Patel S, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. *Nature*. 2022;601:446–51. <https://doi.org/10.1038/s41586-021-04234-3>
- Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9:654–9. <https://doi.org/10.1038/ncb1596>
- Das S, Abdel-Mageed AB, Adamidi C, Adelson PD, Akat KM, Alsop E, et al. The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. *Cell*. 2019;177:231–42. <https://doi.org/10.1016/j.cell.2019.03.023>
- Taussig G, Aufaure P, Pilliard D. [Tendon surgery in equinovarus deformity of the foot in children and adolescents with cerebral palsy]. *Rev Chir Orthop Reparatrice Appar Mot*. 1990;76:128–36.
- Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. *Clin Chem*. 2010;56:1733–41. <https://doi.org/10.1373/clinchem.2010.147405>
- Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature*. 2017;542:450–5. <https://doi.org/10.1038/nature21365>
- Song SJ, Song MS, Ala U, Webster K, Ng C, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. *Cell*. 2013;154:311–24. <https://doi.org/10.1016/j.cell.2013.06.026>
- Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. *Neuroreport*. 2007;18:297–300. <https://doi.org/10.1097/WNR.0b013e3280148e8b>
- Young-Pearse TL, Lee H, Hsieh YC, Chou V, Selkoe DJ. Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer's disease. *Trends Neurosci*. 2023;46:426–44. <https://doi.org/10.1016/j.tins.2023.03.005>
- Duraiarajan S, Selvarasu K, Singh AK, Patnaik S, Iyaswamy A, Jaiswal Y, et al. Unraveling the interplay of kinesin-1, tau, and microtubules in neurodegeneration associated with Alzheimer's disease. *Front Cell Neurosci*. 2024;18:1432002. <https://doi.org/10.3389/fncel.2024.1432002>
- Reiss AB, Housny M, Gulkarov S, Hossain T, Locke B, Srivastava A, et al. Role of apolipoprotein e in alzheimer's disease pathogenesis, prognosis and treatment. *Discov Med*. 2024;36:1917–32. <https://doi.org/10.24976/Discov.Med.202436189.179>
- Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease? *Nat Rev Neurol*. 2020;16:193–7. <https://doi.org/10.1038/s41582-020-0323-9>
- Lanni C, Masi M, Racchi M, Govoni S. Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways. *Mol Psychiatry*. 2021;26:280–95. <https://doi.org/10.1038/s41380-020-0760-2>
- Bassil DT, Zheng B, Su B, Kafetsouli D, Udeh-Momoh C, Tzoulaki I, et al. Lower incidence of dementia following cancer diagnoses: evidence from a large cohort and mendelian randomization study. *J Prev Alzheimers Dis*. 2024;11:1397–405. <https://doi.org/10.14283/jpad.2024.135>
- Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor

- protein-cleaving enzyme 1. *J Neurosci.* 2008;28:1213–23. <https://doi.org/10.1523/JNEUROSCI.5065-07.2008>
18. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. *J Alzheimers Dis.* 2008;14:27–41. <https://doi.org/10.3233/jad-2008-14103>
 19. Sheinerman KS, Tsvinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment. *Aging.* 2012;4:590–605. <https://doi.org/10.18632/aging.100486>
 20. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. *Exp Neurol.* 2012;235:491–6. <https://doi.org/10.1016/j.expneurol.2011.11.026>
 21. Čarna M, Novotný JS, Dragišić N, Slavik H, Sheardova K, Geda YE, et al. Misrouting of plasma miRNAs in aging and Alzheimer's disease. *J Neurochem.* 2023;165:149–61. <https://doi.org/10.1111/jnc.15801>
 22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol.* 2021;74:790–799. <https://doi.org/10.1016/j.rec.2021.07.010>
 23. Cochrane Handbook for Systematic Reviews of Intervention. (John Wiley & Sons, Chichester UK, 2019).
 24. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P in 3rd Symposium on Systematic Reviews: Beyond the Basics; 2000 Jul 3-5; Oxford, UK (2000).
 25. Llambrich M, Correig E, Guma J, Brezmes J, Cumeras R. Amanida: an R package for meta-analysis of metabolomics non-integral data. *Bioinformatics.* 2022;38:583–5. <https://doi.org/10.1093/bioinformatics/btab591>
 26. De Toma I, Sierra C, Dierssen M. Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome. *PLoS Comput Biol.* 2021;17:e1009317. <https://doi.org/10.1371/journal.pcbi.1009317>
 27. Kern F, Aparicio-Puerta E, Li Y, Fehlmann T, Kehl T, Wagner V, et al. miRTargetLink 2.0-interactive miRNA target gene and target pathway networks. *Nucleic Acids Res.* 2021;49:W409–16. <https://doi.org/10.1093/nar/gkab297>
 28. Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. *Bioinformatics.* 2020;36:2628–9. <https://doi.org/10.1093/bioinformatics/btz931>
 29. Rishik S, Hirsch P, Grandke F, Fehlmann T, Keller A. miRNATissueAtlas 2025: an update to the uniformly processed and annotated human and mouse non-coding RNA tissue atlas. *Nucleic Acids Res.* 2025;53:D129–37. <https://doi.org/10.1093/nar/gkae1036>
 30. Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. *PLoS Biol.* 2012;10:e1001450. <https://doi.org/10.1371/journal.pbio.1001450>
 31. Nie C, Sun Y, Zhen H, Guo M, Ye J, Liu Z, et al. Differential Expression of Plasma Exo-miRNA in Neurodegenerative Diseases by Next-Generation Sequencing. *Front Neurosci.* 2020;14:438. <https://doi.org/10.3389/fnins.2020.00438>
 32. Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. *PLoS One.* 2015;10:e0139233. <https://doi.org/10.1371/journal.pone.0139233>
 33. Wang L, Zhen H, Sun Y, Rong S, Li B, Song Z, et al. Plasma Exo-miRNAs Correlated with AD-Related factors of Chinese individuals involved in abeta accumulation and cognition decline. *Mol Neurobiol.* 2022;59:6790–804. <https://doi.org/10.1007/s12035-022-03012-0>
 34. Fitz NF, Wang J, Kamboh MI, Koldamova R, Lefterov I. Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer's disease. *Neurobiol Dis.* 2021;159:105481. <https://doi.org/10.1016/j.nbd.2021.105481>
 35. Shigemizu D, Akiyama S, Asanomi Y, Boroevich KA, Sharma A, Tsunoda T, et al. Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. *Commun Biol.* 2019;2:77. <https://doi.org/10.1038/s42003-019-0324-7>
 36. Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML, et al. Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. *PLoS One.* 2018;13:e0197329. <https://doi.org/10.1371/journal.pone.0197329>
 37. Ludwig N, Fehlmann T, Kern F, Gogol M, Maetzler W, Deutscher S, et al. Machine learning to detect Alzheimer's disease from circulating non-coding RNAs. *Genomics Proteom Bioinforma.* 2019;17:430–40. <https://doi.org/10.1016/j.gpb.2019.09.004>
 38. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. *Genome Biol.* 2013;14:R78. <https://doi.org/10.1186/gb-2013-14-7-r78>
 39. Zhai W, Zhao M, Wei C, Zhang G, Qi Y, Zhao A, et al. Biomarker profiling to determine clinical impact of microRNAs in cognitive disorders. *Sci Rep.* 2024;14:8270. <https://doi.org/10.1038/s41598-024-58882-2>
 40. Palade J, Alsop E, Courtright-Lim A, Hsieh M, Whitsett TG, Galasko D, et al. Small RNA changes in plasma have potential for early diagnosis of Alzheimer's disease before symptom onset. *Cells.* 2024;13:207. <https://doi.org/10.3390/cells13030207>
 41. Dong Z, Gu H, Guo Q, Liang S, Xue J, Yao F, et al. Profiling of serum exosome miRNA reveals the potential of a miRNA panel as diagnostic biomarker for Alzheimer's disease. *Mol Neurobiol.* 2021;58:3084–94. <https://doi.org/10.1007/s12035-021-02323-y>
 42. Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. *Hum Mol Genet.* 2017;26:3808–22. <https://doi.org/10.1093/hmg/ddx267>
 43. Lu L, Dai WZ, Zhu XC, Ma T. Analysis of Serum miRNAs in Alzheimer's Disease. *Am J Alzheimers Dis Other Dement.* 2021;36:15333175211021712. <https://doi.org/10.1177/15333175211021712>
 44. Wu H, Thalamuthu A, Cheng L, Fowler C, Masters CL, Sachdev P, et al. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. *Alzheimers Res Ther.* 2020;12:59. <https://doi.org/10.1186/s13195-020-00627-0>
 45. Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, et al. Validating Alzheimer's disease micro RNAs using next-generation sequencing. *Alzheimers Dement.* 2016;12:565–76. <https://doi.org/10.1016/j.jalz.2015.12.012>
 46. Batabyal RA, Bansal A, Cechinel LR, Authet K, Goldberg M, Nadler E, et al. Adipocyte-Derived small extracellular vesicles from patients with Alzheimer disease carry miRNAs predicted to target the CREB signaling pathway in neurons. *Int J Mol Sci.* 2023;24:14024. <https://doi.org/10.3390/ijms241814024>
 47. Visconte C, Fenoglio C, Serpente M, Muti P, Sacconi A, Rigoni M, et al. Altered Extracellular vesicle miRNA profile in prodromal Alzheimer's disease. *Int J Mol Sci.* 2023;24:14749. <https://doi.org/10.3390/ijms241914749>
 48. Wen Q, Wittens M, Engelborghs S, van Herwijnen M, Tsamou M, Roggen E, et al. Beyond CSF and neuroimaging assessment: evaluating plasma miR-145-5p as a potential biomarker for mild cognitive impairment and Alzheimer's disease. *ACS Chem Neurosci.* 2024;15:1042–54. <https://doi.org/10.1021/acscchemneuro.3c00740>
 49. Dong H, Li J, Huang L, Chen X, Li D, Wang T, et al. Serum MicroRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease. *Dis Markers.* 2015;2015:625659. <https://doi.org/10.1155/2015/625659>
 50. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, et al. MicroRNAs can regulate human APP levels. *Mol Neurodegener.* 2008;3:10. <https://doi.org/10.1186/1750-1326-3-10>
 51. Xu H, Liu X, Li W, Xi Y, Su P, Meng B, et al. p38 MAPK-mediated loss of nuclear RNase III enzyme Drosha underlies amyloid beta-induced neuronal stress in Alzheimer's disease. *Aging Cell.* 2021;20:e13434. <https://doi.org/10.1111/acer.13434>
 52. Hébert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahatoglu AN, et al. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. *Hum Mol Genet.* 2010;19:3959–69. <https://doi.org/10.1093/hmg/ddq311>
 53. Gibbings D, Voinnet O. Control of RNA silencing and localization by endolysosomes. *Trends Cell Biol.* 2010;20:491–501. <https://doi.org/10.1016/j.tcb.2010.06.001>
 54. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. *Nat Cell Biol.* 2009;11:1143–9. <https://doi.org/10.1038/ncb1929>
 55. Yamakawa A, Suganuma M, Mitsumori R, Niida S, Ozaki K, Shigemizu D. Alzheimer's disease may develop from changes in the immune system, cell cycle, and protein processing following alterations in ribosome function. *Sci Rep.* 2025;15:3838. <https://doi.org/10.1038/s41598-025-88526-y>
 56. Campanelli L, Galeano P, Prestia FA, Cuesta C, Dalmaso MC, Flores-López M, et al. Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease. *Heliyon.* 2025;11:e41725. <https://doi.org/10.1016/j.heliyon.2025.e41725>
 57. Lee JK, Raghavan S, Christenson LR, Frank RD, Kantarci K, Rocca WA, et al. Longitudinal associations of reproductive factors and exogenous estrogens with neuroimaging biomarkers of Alzheimer's disease and cerebrovascular disease. *Alzheimers Dement.* 2024;20:4613–24. <https://doi.org/10.1002/alz.13890>
 58. Bucht G, Adolfsson R, Lithner F, Winblad B. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. *Acta Med Scand.* 1983;213:387–92. <https://doi.org/10.1111/j.0954-6820.1983.tb03756.x>
 59. Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. *Biol Psychiatry.* 1991;30:1219–28. [https://doi.org/10.1016/0006-3223\(91\)90158-i](https://doi.org/10.1016/0006-3223(91)90158-i)
 60. Chow HM, Shi M, Cheng A, Gao Y, Chen G, Song X, et al. Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. *Nat Neurosci.* 2019;22:1806–19. <https://doi.org/10.1038/s41593-019-0505-1>
 61. Perry EK, Blessed G, Tomlinson BE, Perry RH, Crow TJ, Cross AJ, et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. *Neurobiol Aging.* 1981;2:251–6. [https://doi.org/10.1016/0197-4580\(81\)90032-4](https://doi.org/10.1016/0197-4580(81)90032-4)

62. Mazurek MF, Beal MF. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. *Neurology*. 1991;41:716–9. <https://doi.org/10.1212/wnl.41.5.716>
63. Plagman A, Hoscheidt S, McLimans KE, Klinedinst B, Pappas C, Anantharam V, et al. Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance. *Neurobiol Aging*. 2019;76:201–7. <https://doi.org/10.1016/j.neurobiolaging.2019.01.002>
64. Woo JA, Roh SE, Lakshmana MK, Kang DE. Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly. *FASEB J*. 2012;26:1672–81. <https://doi.org/10.1096/fj.11-194423>
65. Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, et al. The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer's disease. *Nature*. 2020;586:735–40. <https://doi.org/10.1038/s41586-020-2681-2>
66. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. Changes of p53 in the brains of patients with Alzheimer's disease. *Biochem Biophys Res Commun*. 1997;232:418–21. <https://doi.org/10.1006/bbrc.1997.6301>
67. Wolfrum P, Fietz A, Schnichels S, Hurst J. The function of p53 and its role in Alzheimer's and Parkinson's disease compared to age-related macular degeneration. *Front Neurosci*. 2022;16:1029473. <https://doi.org/10.3389/fnins.2022.1029473>
68. Tsartsalis S, Slevén H, Fancy N, Wessely F, Smith AM, Willumsen N, et al. A single nuclear transcriptomic characterisation of mechanisms responsible for impaired angiogenesis and blood-brain barrier function in Alzheimer's disease. *Nat Commun*. 2024;15:2243. <https://doi.org/10.1038/s41467-024-46630-z>

AUTHOR CONTRIBUTIONS

The authors contributed to this article as follows: Conceptualization: GBS, Methodology: JSN, MC Investigation: JSN, Data curation: JSN, MC, Formal analysis: JSN, MC, Funding acquisition: GBS, Visualization: JSN, MC, Writing - original draft: JSN, MC, GBS, Writing - Review & Editing: EBD, ZM.

FUNDING

The study was funded by the European Union: Next Generation EU – Project National Institute for Neurological Research (LX22NPO5107 (MEYS)). Open access publishing supported by the institutions participating in the CzechELib Transformative Agreement.

COMPETING INTERESTS

The authors declare no competing interests.

AUTHORS' NOTE

No humans or animal models were used in our research.

OPEN SCIENCE STATEMENT

In this study, we adhere to the principles of Open Science as much as possible: we explicitly labelled the study as meta-analysis, we report the source studies used in meta-analysis, the data are available within the paper and its supplementary materials, the R script of the analysis is available on request from the first author, and all materials used are cited.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-026-03487-6>.

Correspondence and requests for materials should be addressed to GB Stokin.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026